

3rd Immune Effector Cell Therapies in Multiple Myeloma Workshop

MAY 7-8, 2022 • BOSTON, MA • WESTIN BOSTON SEAPORT DISTRICT AND VIRTUAL

Saturday, May 7, 2022

8:00-8:15 am	Introduction and Welcome	Adam Cohen, Hermann Einsele, Nikhil Munshi
8:15-8:45 am	Plenary Talk: Next generation CAR designs	Michel Sadelain
SESSION 1:	Clinical updates on CAR T cells	
8:45-10:15 am	Session chairs: Caitlin Costello and Nikhil Munshi	
8:45-9:00 am	Update on ide-cel data	Nina Shah
9:00-9:15 am	Update on cilta-cel data	Jesus Berdeja
9:15-9:30 am	Update on other BCMA CAR T cell products	Krina Patel
9:30-10:15 am	Discussion	Session Faculty
10:15-10:45 pm	Break	
SESSION 2:	Clinical updates on Bispecific Antibodies/T-cell engagers	
10:45 -12:15 pm	Session chairs: Ajai Chari and Philippe Moreau	
10:45-11:00 am	BCMA bispecifics part 1: Teclistamab, Elranatamab, AMG701	Saad Usmani
11:00-11:15 am	BCMA bispecifics part 2: REGN5458, TNB-383B, HPN217, CC-93269	Cesar Rodriguez
11:15-11:30 am	Non-BCMA bispecifics and other novel approaches	Ajai Chari
11:30-12:15 pm	Discussion	Session Faculty + Amrita krishnan
12:15-1:00 pm	Lunch	
SESSION 3:	Sequencing immunotherapies in MM	
1:00-2:30 pm	Session chairs: Noopur Raje and Paula Rodriguez-Otero	
1:00-1:15 pm	BCMA expression and loss in myeloma	Mehmet Samur
1:15-1:30 pm	Outcomes after failure of CAR T or bispecific Ab therapies	Ken Anderson
1:30-1:45 pm	Serial use of BCMA-directed therapies: what are the data?	Adam Cohen
1:45-2:30 pm	Discussion	Session Faculty
SESSION 4:	Optimal combinations for CAR T and BsAb/TCE therapies	
2:30-4:00 pm	Session chairs: Sundar Jagannath and Kwee Yong	
2:30-2:45 pm	Strategies to augment BCMA directed (CAR-T) therapies	Michael Hudecek
2:45-3:00 pm	Combining CAR T cell products with each other and IMiDs	Kailin Xu
3:00-3:15 pm	Optimal drug partners for BsAb therapies	Neils van de Donk
3:15-4:00 pm	Discussion	Session Faculty + Simon Harrison
4:00 PM	Adjourn for day	

Sunday, May 8, 2022

8:00-8:05 am

Welcome to day 2

Adam Cohen, Hermann
Einsele, Nikhil Munshi

SESSION 5: Alternative CAR approaches

8:05-9:05 am

Session chairs: David Avigan and Nizar Bahlis

8:05-8:15 am

Dual-targeted CAR T cells

Eric Smith

8:15-8:25 am

Allogeneic CAR T cell approaches in myeloma

Binod Dhakal

8:25-8:35 am

Update on CAR-NK cell therapies

Paul Lin

8:35-9:05 am

Discussion

Session Faculty

SESSION 6: New technologies: Designing the next CARs and BsAbs

9:05-10:15 am

Session chair: Tuna Mutis and Nikhil Munshi

9:05-9:15 am

Novel CAR and costimulatory receptor designs

Maria Themeli

9:15-9:25 am

Novel approaches to CAR T cell manufacturing

Michael Milone

9:35-9:45 am

CD47-targeted bispecific antibodies

Stefano Sammiceli

9:45-10:15 am

Discussion

Session Faculty +
Michael Hudecek

10:15-10:45 am

Break

SESSION 7: Determinants of response/resistance

10:45am-12:15pm

Session chairs: Hermann Einsele and Yi Lin

10:45-10:56 am

Predictors of Durable Response to ide-cel

Shari Kaiser

10:56-11:07 am

Predictors of Durable Response to cilta-cel

Enrique Zudaire

11:07-11:18 am

Profiling MM and immune cells in BsAb therapy

Paola Neri

11:18-11:30 am

Profiling MM and Immune cells in CAR T cell therapy

Samir Parekh

11:30am-12:15pm

Discussion

12:15-1:00 pm

Lunch

SESSION 8: Managing toxicities of T cell directed therapies

1:00-2:00 pm

Session chairs: Surbhi Sidana and Tom Martin

1:00-1:10 pm

COVID-19 vaccine responses post-CART and BsAb therapy

Oliver van Oekelen

1:10-1:20 pm

Infections post-CAR T and BsAb therapy

Sarah Hammond

1:20-1:30 pm

Update on ICANS and other neurotoxicities

Bianca Santomosso

1:30 - 2:00 pm

Discussion

Session Faculty

SESSION 9: Workshop on HLH/MAS

2:00-2:45 pm

Session chairs: Adam Cohen and Nikhil Munshi

2:00-2:10 pm

Clinical characteristics of HLH/MAS post-BCMA CAR T

Deepu Madduri

2:10-2:20 pm

Identifying and managing CAR T-associated HLH/MAS

Sandy Wong

2:20-2:45pm

Discussion

Session Faculty +
Noelle Frey and
Hermann Einsele

2:45-3:00 pm

Wrap-up and adjourn

Thank you to our sponsors

PLATINUM



GOLD



SILVER

